GlobalAcorn’s cancer therapeutic platform is comprised of two technologies. The nanoparticle drug delivery platform has been created to deliver drugs to their target sites and, by either taking advantage of the local conditions, such as local chemistry or delivering exogenous changes, such as delivery of heat, thereby releasing them at the site where they need to be. In addition, the nanoparticle vehicles are labelled so that they can be visualised using standard clinical imaging technology, such as magnetic resonance imaging (MRI).
The second platform technology is the creation of a novel class of bioactive molecules that can be designed to specifically target multiple important proteins involved in the growth of cancer cells. Because of the flexibility of this platform GlobalAcorn has been able to demonstrate activity against multiple therapeutic targets. GlobalAcorn’s nanoparticle delivery systems represent the ideal delivery vehicle for these bioactive molecules.
We have designed active and passively targeted lipid-based nanoparticles with varied chemical and physical properties, such as particle size, surface properties, ligand density, therapeutic payload and release profile, using a self-assembly nanoparticle formulation process. GlobalAcorn designs lipid-based nanoparticles with optimal performance properties using an interactive process that includes in vitro drug release, PK, tolerability, bio-distribution, targeting, controlled release and efficacy studies.
Tumour detection and diagnosis are vital steps in cancer management. One method is by utilization of Magnetic Resonance Imaging (MRI), which is among the best non-invasive techniques in clinical medicine for assessing the anatomy and physiology of the body. MRI is enhanced by use of a contrast agent to aid in tumour identification. Traditional imaging agents are not very effective in detecting primary metastatic tumours and cells due to a lack of both specificity and sensitivity.
Active tissue targeting is achieved by using targeting ligands on the surface of the nanoparticle that binds to specific cell surfaces of tissue markers. Passive tissue targeting nanoparticles take advantage of the unique pathophysiological characteristics of tumour vessels, enabling nanoparticle accumulation by ‘leaky’ vascularisation called the EPR effect (Enhanced Permeability and Retention). A targeted nanoparticle is also incorporated with an imaging agent, when engineered with a specific coating, bind particularly well to the tumour and could be a powerful tool for diagnosis. Lipid-based nanoparticles offer a very high potential to be used in combination with an MRI contrast agent due to their bio-distribution, biocompatibility and high loading benefits.